A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy

NCT03641560 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration Resistant Prostate Cancer

Interventions

DRUG: Enzalutamide
DRUG: Androgen deprivation therapy (ADT)

Sponsor

Astellas Pharma Inc